<table cellpadding="2" cellspacing="0" frame="void" id="t10265122" rules="none" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<colgroup>
<col width="30%"></col>
<col width="30%"></col>
<col width="40%"></col>
</colgroup>
<tfoot>
<tr>
<td align="left" colspan="3">↑ increase, ↓ decrease, ↔ no change,
↕ unable to predict</td>
</tr>
</tfoot>
<tbody>
<tr>
<td align="left" stylecode="Toprule Botrule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Concomitant Drug Class:<br/>Drug name</content>
</content>
</td>
<td stylecode="Toprule Botrule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Effect on
Concentration of Tipranavir or Concomitant Drug</content>
</content>
</td>
<td stylecode="Toprule Botrule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Clinical Comment</content>
</content>
</td>
</tr>
<tr>
<td colspan="3" stylecode="Toprule Botrule">
<br/>HIV-1 Antiviral
Agents</td>
</tr>
<tr>
<td>
<content stylecode="bold">
<content stylecode="emphasis">Fusion Inhibitors:</content>
</content> </td>
<td colspan="2"> </td>
</tr>
<tr>
<td stylecode="Botrule" valign="top">
<br/>Enfuvirtide</td>
<td stylecode="Botrule" valign="top">
<br/>↑ Tipranavir</td>
<td stylecode="Botrule">At steady state, tipranavir trough concentrations
were approximately 45% higher in patients co-administered enfuvirtide
in the Phase 3 trials.  The mechanism for this increase is not known.
 Dose adjustments are not recommended.</td>
</tr>
<tr>
<td colspan="3" stylecode="Toprule" valign="top">
<content stylecode="bold">Non-Nucleoside
Reverse Transcriptase</content>
</td>
</tr>
<tr>
<td valign="top">
<content stylecode="bold">Inhibitors:</content>
</td>
<td valign="top"> </td>
<td> </td>
</tr>
<tr>
<td valign="top">
<br/>Etravirine</td>
<td valign="top">
<br/>↓ Etravirine</td>
<td>
<br/>APTIVUS/ritonavir when coadministered with etravirine
may cause a significant decrease in the plasma concentrations of etravirine
and loss of therapeutic effect of etravirine.  Etravirine and APTIVUS/ritonavir
should not be coadministered.</td>
</tr>
<tr>
<td colspan="3" valign="top"> </td>
</tr>
<tr>
<td valign="top">Rilpivirine</td>
<td valign="top">The use of rilpivirine co-administered with APTIVUS/ritonavir
has not been studied.</td>
<td>Concomitant use of rilpivirine with Aptivus/ritonavir may cause
an increase in the plasma concentrations of rilpivirine (inhibition
of CYP3A enzymes).  Rilpivirine is not expected to affect the plasma
concentrations of Aptivus/ritonavir.</td>
</tr>
<tr>
<td colspan="3" valign="top"> </td>
</tr>
<tr>
<td colspan="3" stylecode="Toprule">
<content stylecode="bold">
<content stylecode="emphasis">Nucleoside Reverse
Transcriptase </content>
</content>   </td>
</tr>
<tr>
<td>
<content stylecode="bold">Inhibitors:</content>
</td>
<td colspan="2"> </td>
</tr>
<tr>
<td valign="top">
<br/>Abacavir</td>
<td valign="top">
<br/>↓ Abacavir AUC by approximately 40%</td>
<td>
<br/>Clinical relevance of reduction in abacavir levels
not established. Dose adjustment of abacavir cannot be recommended
at this time.</td>
</tr>
<tr>
<td colspan="3"> </td>
</tr>
<tr>
<td valign="top">Didanosine (EC)</td>
<td valign="top">↓ Didanosine</td>
<td>Clinical relevance of reduction in didanosine levels not established.
For optimal absorption, didanosine should be separated from APTIVUS/ritonavir
dosing by at least 2 hours.</td>
</tr>
<tr>
<td colspan="3"> </td>
</tr>
<tr>
<td valign="top">Zidovudine</td>
<td valign="top">↓ Zidovudine AUC by approximately 35%. ZDV glucuronide
concentrations were unaltered.</td>
<td>Clinical relevance of reduction in zidovudine levels not established.
Dose adjustment of zidovudine cannot be recommended at this time.</td>
</tr>
<tr>
<td stylecode="Toprule">
<content stylecode="bold">
<content stylecode="emphasis">Protease Inhibitors (co-administered
with 200 mg of ritonavir):</content>
</content>
<br/> </td>
<td colspan="2" stylecode="Toprule"> </td>
</tr>
<tr>
<td valign="top">Fosamprenavir<br/>Lopinavir<br/>Saquinavir</td>
<td valign="top">↓ Amprenavir<br/>↓ Lopinavir<br/>↓
Saquinavir</td>
<td valign="top">Combining a protease inhibitor with APTIVUS/ritonavir
is not recommended.</td>
</tr>
<tr>
<td>
<br/>
<content stylecode="bold">
<content stylecode="emphasis">Protease Inhibitors (co-administered
with 100 mg of ritonavir):</content>
</content>
<br/> </td>
<td colspan="2"> </td>
</tr>
<tr>
<td stylecode="Botrule" valign="top">Atazanavir</td>
<td stylecode="Botrule" valign="top">↓ Atazanavir<br/>↑ Tipranavir</td>
<td stylecode="Botrule"> </td>
</tr>
<tr>
<td valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Virus Integrase Strand Transfer Inhibitors:</content>
</content>
<br/> </td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr>
<td stylecode="Botrule" valign="top">Raltegravir</td>
<td stylecode="Botrule" valign="top">↓ Raltegravir</td>
<td stylecode="Botrule" valign="top">APTIVUS/ritonavir reduces plasma
concentrations of raltegravir.  Since comparable efficacy was observed
for this combination in phase 3 studies, dose adjustment is not recommended.</td>
</tr>
<tr>
<td stylecode="Botrule">
<br/>Agents for Opportunistic Infections</td>
<td colspan="2" stylecode="Botrule"> </td>
</tr>
<tr>
<td valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Antifungals:</content>
</content>
<br/> </td>
<td colspan="2"> </td>
</tr>
<tr>
<td rowspan="5" stylecode="Botrule" valign="top">Fluconazole<br/>Itraconazole<br/>Ketoconazole<br/>Voriconazole</td>
<td valign="top">↑ Tipranavir, ↔ Fluconazole</td>
<td valign="top">Fluconazole increases tipranavir concentrations but
dose adjustments are not needed. Fluconazole doses &gt;200 mg/day are
not recommended.</td>
</tr>
<tr>
<td>↑ Itraconazole (not studied)</td>
<td> </td>
</tr>
<tr>
<td valign="top">↑ Ketoconazole (not studied)</td>
<td valign="top">Based on theoretical considerations itraconazole
and ketoconazole should be used with caution. High doses (&gt;200 mg/day)
are not recommended.</td>
</tr>
<tr>
<td>↕ Voriconazole (not studied)</td>
<td> </td>
</tr>
<tr>
<td stylecode="Botrule" valign="top"> </td>
<td stylecode="Botrule" valign="top">Due to multiple enzymes involved
with voriconazole metabolism, it is difficult to predict the interaction.</td>
</tr>
<tr>
<td stylecode="Toprule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Antimycobacterials:</content>
</content>
<br/> </td>
<td colspan="2"> </td>
</tr>
<tr>
<td valign="top">Clarithromycin</td>
<td valign="top">↑ Tipranavir, ↑ Clarithromycin, <br/>↓ 14-hydroxy-clarithromycin
metabolite</td>
<td valign="top">No dose adjustment of APTIVUS or clarithromycin for
patients with normal renal function is necessary.<br/> </td>
</tr>
<tr>
<td colspan="2"> </td>
<td>For patients with renal impairment the following dosage adjustments
should be considered: <list id="l12035122" listtype="unordered" stylecode="Disc">
<item>For patients with CL<sub>CR</sub> 30 to 60 mL/min
the dose of clarithromycin should be reduced by 50%.</item>
<item>For patients with CL<sub>CR</sub> &lt;30 mL/min
the dose of clarithromycin should be decreased by 75%. </item>
</list>
</td>
</tr>
<tr>
<td valign="top">Rifabutin</td>
<td valign="top">Tipranavir not changed, <br/>↑ Rifabutin <br/>↑ Desacetyl-rifabutin</td>
<td>Single dose study. Dosage reductions of rifabutin by 75% are recommended
(e.g., 150 mg every other day). Increased monitoring for adverse events
in patients receiving the combination is warranted. Further dosage
reduction may be necessary. </td>
</tr>
<tr>
<td stylecode="Toprule Botrule" valign="bottom"> <br/>Other Agents
Commonly Used</td>
<td colspan="2" stylecode="Toprule Botrule"> </td>
</tr>
<tr>
<td colspan="3">
<content stylecode="bold">
<content stylecode="emphasis">Anticonvulsants:</content>
</content>
<br/> </td>
</tr>
<tr>
<td valign="top">Carbamazepine<br/>Phenobarbital<br/>Phenytoin</td>
<td valign="top">↓ Tipranavir</td>
<td valign="top">Caution should be used when prescribing carbamazepine,
phenobarbital and/or phenytoin. APTIVUS may be less effective due
to decreased tipranavir plasma concentration in patients taking these
agents concomitantly.</td>
</tr>
<tr>
<td colspan="3"> </td>
</tr>
<tr>
<td stylecode="Botrule" valign="top">Valproic Acid</td>
<td stylecode="Botrule" valign="top">↓ Valproic Acid</td>
<td stylecode="Botrule">Caution should be used when prescribing valproic
acid. Valproic acid may be less effective due to decreased valproic
acid plasma concentration in patients taking APTIVUS concomitantly.</td>
</tr>
<tr>
<td stylecode="Toprule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Antidepressants:</content>
</content>
</td>
<td stylecode="Toprule" valign="top"> </td>
<td stylecode="Toprule"> </td>
</tr>
<tr>
<td colspan="3" valign="top"> </td>
</tr>
<tr>
<td valign="top">Trazodone</td>
<td valign="top">↑ Trazodone</td>
<td>Concomitant use of trazodone and APTIVUS/ritonavir may increase
plasma concentrations of trazodone. Adverse events of nausea, dizziness,
hypotension, and syncope have been observed following co-administration
of trazodone and ritonavir. If trazodone is used with a CYP 3A4 inhibitor
such as APTIVUS/ritonavir, the combination should be used with caution
and a lower dose of trazodone should be considered.</td>
</tr>
<tr>
<td colspan="3"> </td>
</tr>
<tr>
<td valign="top">Desipramine</td>
<td valign="top">Combination with APTIVUS/ritonavir not studied<br/>↑ Desipramine</td>
<td valign="top">Dosage reduction and concentration monitoring of
desipramine is recommended.</td>
</tr>
<tr>
<td colspan="3"> </td>
</tr>
<tr>
<td valign="top">Selective Serotonin-Reuptake Inhibitors:</td>
<td valign="top">Combination with APTIVUS/ritonavir not studied</td>
<td valign="top">Antidepressants have a wide therapeutic index, but
doses may need to be adjusted upon initiation of APTIVUS/ritonavir
therapy.</td>
</tr>
<tr>
<td valign="top">Fluoxetine<br/>Paroxetine<br/>Sertraline</td>
<td valign="top">↑ Fluoxetine<br/>↑ Paroxetine<br/>↑
Sertraline</td>
<td> </td>
</tr>
<tr>
<td colspan="3" stylecode="Toprule" valign="top">
<content stylecode="bold">Anti-HCV agents:</content>
</td>
</tr>
<tr>
<td colspan="3" valign="top"> </td>
</tr>
<tr>
<td valign="top">Boceprevir</td>
<td valign="top">Co-administration of APTIVUS and boceprevir has not
been studied.</td>
<td>With concomitant use, changes in exposure were observed both for
boceprevir and certain protease inhibitors used for the treatment
of HIV-1 infection or either medication.  Information is not available
regarding tipranavir or boceprevir exposure with concomitant use.
  It is not recommended to co-administer boceprevir with APTIVUS/ritonavir.<br/>
<br/>
</td>
</tr>
<tr>
<td valign="top">Telaprevir</td>
<td valign="top">Co-administration of APTIVUS and telaprevir has not
been studied.</td>
<td>With concomitant use, changes in exposure were observed both for
telaprevir and certain protease inhibitors used for the treatment
of HIV-1 infection or telaprevir.  Information is not available regarding
tipranavir or telaprevir exposure with concomitant use.  It is not
recommended to co-administer telaprevir with APTIVUS/ritonavir.</td>
</tr>
<tr>
<td colspan="3" valign="top"> </td>
</tr>
<tr>
<td colspan="3" stylecode="Toprule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Anti-gout:</content>
</content>
</td>
</tr>
<tr>
<td colspan="3" valign="top"> </td>
</tr>
<tr>
<td valign="top">Colchicine</td>
<td valign="top">↑ Colchicine</td>
<td>In patients with renal or hepatic impairment, coadministration
of colchicine in patients on APTIVUS/ritonavir is contraindicated.<br/>
<br/>In combination with APTIVUS/ritonavir, the following
dosage adjustments are recommended in patients with normal renal and
hepatic function:<br/>
<br/>
<content stylecode="underline">
<content stylecode="emphasis">Treatment
of gout flares: Co-administration of colchicine in patients on APTIVUS/ritonavir:</content>
</content>
<list id="l12845122" listtype="unordered" stylecode="Disc">
<item>0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (half tablet)
1 hour later. Dose to be repeated no earlier than 3 days.</item>
</list>
<content stylecode="underline">
<content stylecode="emphasis">Prophylaxis of gout flares:  Co-administration
of colchicine in patients on APTIVUS/ritonavir</content>
</content>:<list id="l13062122" listtype="unordered" stylecode="Disc">
<item>If the original colchicine regimen was 0.6 mg twice a day,
the regimen should be adjusted to 0.3 mg once a day.</item>
<item>If the original colchicine regimen was 0.6 mg once a day,
the regimen should be adjusted to 0.3 mg once every other day.</item>
</list>
<content stylecode="underline">
<content stylecode="emphasis">Treatment of familial Mediterranean fever
(FMF):  Co-administration of colchicine in patients on APTIVUS/ritonavir:</content>
</content>
<list id="l13075122" listtype="unordered" stylecode="Disc">
<item>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice
a day).</item>
</list>
</td>
</tr>
<tr>
<td colspan="3" stylecode="Toprule" valign="top">
<content stylecode="bold">Antipsychotics:</content>
</td>
</tr>
<tr>
<td colspan="3" valign="top"> </td>
</tr>
<tr>
<td valign="top">Quetiapine</td>
<td valign="top">↑ Quetiapine</td>
<td>
<content stylecode="underline">Initiation of APTIVUS with ritonavir in patients taking
quetiapine:</content>
<br/>
<br/>Consider alternative
antiretroviral therapy to avoid increases in quetiapine exposures.
If coadministration is necessary, reduce the quetiapine dose to 1/6
of the current dose and monitor for quetiapine-associated adverse
reactions. Refer to the quetiapine prescribing information for recommendations
on adverse reaction monitoring.<br/>
<br/>
<content stylecode="underline">Initiation of quetiapine in patients taking APTIVUS with ritonavir:</content>
<br/>
<br/>Refer to the quetiapine prescribing information
for initial dosing and titration of quetiapine. </td>
</tr>
<tr>
<td colspan="3" stylecode="Botrule" valign="top"> </td>
</tr>
<tr>
<td stylecode="Toprule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Benzodiazepines:</content>
</content>
</td>
<td colspan="2"> </td>
</tr>
<tr>
<td colspan="3" valign="top"> </td>
</tr>
<tr>
<td valign="top">Parenterally administered midazolam</td>
<td valign="top">↑ Midazolam</td>
<td valign="top">Midazolam is extensively metabolized by CYP 3A4.
Increases in the concentration of midazolam are expected to be significantly
higher with oral than parenteral administration. Therefore, APTIVUS
should not be given with orally administered midazolam [<content stylecode="italics">
<content stylecode="emphasis">see Contraindications <linkhtml href="#Section_4">(4)</linkhtml>
</content>
</content>]. If APTIVUS is co-administered with parenteral midazolam,
close clinical monitoring for respiratory depression and/or prolonged
sedation should be exercised and dosage adjustments should be considered.</td>
</tr>
<tr>
<td stylecode="Toprule" valign="top">Buprenorphine/naloxone</td>
<td stylecode="Toprule" valign="top">↔ Buprenorphine<br/>↓ Tipranavir</td>
<td stylecode="Toprule" valign="top">APTIVUS/ritonavir did not result
in changes in the clinical efficacy of buprenorphine/naloxone.  Compared
to historical controls tipranavir C<sub>min</sub> was
decreased approximately 40% with this combination.  Dose adjustments
cannot be recommended.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Calcium Channel
Blockers:</content>
</content>
<br/>
<br/>Diltiazem<br/>Felodipine<br/>Nicardipine<br/>Nisoldipine<br/>Verapamil</td>
<td stylecode="Toprule  Botrule" valign="top">Combination with APTIVUS/ritonavir
not studied. Cannot predict effect of TPV/ritonavir on calcium channel
blockers that are dual substrates of CYP3A and P-gp due to conflicting
effect of TPV/ritonavir on CYP3A and P-gp.<br/>
<br/>↕
Diltiazem<br/>↑ Felodipine (CYP3A substrate but not P-gp substrate)<br/>↕ Nicardipine<br/>↕ Nisoldipine (CYP3A substrate but not
clear whether it is a P-gp substrate)<br/>↕ Verapamil</td>
<td stylecode="Toprule Botrule" valign="top">Caution is warranted and clinical
monitoring of patients is recommended.</td>
</tr>
<tr>
<td stylecode="Botrule" valign="top">Disulfiram/Metronidazole</td>
<td stylecode="Botrule" valign="top">Combination with TPV/ritonavir
not studied</td>
<td stylecode="Botrule">APTIVUS capsules contain alcohol that can produce
disulfiram-like reactions when co-administered with disulfiram or
other drugs which produce this reaction (e.g., metronidazole).</td>
</tr>
<tr>
<td valign="top">
<content stylecode="bold">Endothelin receptor antagonists</content>
<br/>
<br/>Bosentan</td>
<td valign="top">
<br/>
<br/>↑ Bosentan</td>
<td>
<content stylecode="underline">
<content stylecode="emphasis">Co-administration of bosentan in patients
on APTIVUS/ritonavir:</content>
</content>
<br/>In patients
who have been receiving APTIVUS/ritonavir for at least 10 days, start
bosentan at 62.5 mg once daily or every other day based upon individual
tolerability.<br/>
<br/>
<content stylecode="underline">
<content stylecode="emphasis">Co-administration
of APTIVUS/ritonavir in patients on bosentan:</content>
</content>
<br/>
<br/>Discontinue use of bosentan at least 36 hours
prior to initiation of APTIVUS/ritonavir.<br/>
<br/>After
at least 10 days following the initiation of APTIVUS/ritonavir, resume
bosentan at 62.5 mg once daily or every other day based upon individual
tolerability.</td>
</tr>
<tr>
<td colspan="3" valign="top"> </td>
</tr>
<tr>
<td stylecode="Toprule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">HMG-CoA Reductase
Inhibitors:</content>
</content>
<br/> </td>
<td colspan="2" stylecode="Toprule"> </td>
</tr>
<tr>
<td stylecode="Botrule" valign="top">Atorvastatin<br/>Rosuvastatin</td>
<td stylecode="Botrule" valign="top">↑ Atorvastatin<br/>↓ Hydroxy-atorvastatin
metabolites<br/>↑ Rosuvastatin</td>
<td stylecode="Botrule" valign="top">Avoid co-administration with atorvastatin.</td>
</tr>
<tr>
<td stylecode="Toprule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Hypoglycemics:</content>
</content>
<br/> </td>
<td colspan="2" stylecode="Toprule"> </td>
</tr>
<tr>
<td> </td>
<td valign="top">Combination with APTIVUS/ritonavir not studied</td>
<td valign="top">Careful glucose monitoring is warranted.</td>
</tr>
<tr>
<td colspan="3"> </td>
</tr>
<tr>
<td valign="top">Glimepiride<br/>Glipizide<br/>Glyburide<br/>Pioglitazone</td>
<td>↔ Glimepiride (CYP 2C9)<br/>↔ Glipizide (CYP 2C9)<br/>↔ Glyburide (CYP 2C9)<br/>↕ Pioglitazone (CYP 2C8 and CYP
3A4)</td>
<td> </td>
</tr>
<tr>
<td valign="top">Repaglinide</td>
<td valign="top">↕ Repaglinide (CYP 2C8 and CYP 3A4)</td>
<td> </td>
</tr>
<tr>
<td valign="top">Tolbutamide</td>
<td valign="top">↔ Tolbutamide (CYP 2C9)<br/>
<br/>The
effect of TPV/ritonavir on CYP 2C8 substrate is not known.</td>
<td> </td>
</tr>
<tr>
<td stylecode="Toprule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Immunosuppressants:</content>
</content> </td>
<td colspan="2" stylecode="Toprule"> </td>
</tr>
<tr>
<td> </td>
<td valign="top">Combination with APTIVUS/ritonavir not studied. Cannot
predict effect of TPV/ritonavir on immunosuppressants due to conflicting
effect of TPV/ritonavir on CYP 3A and P-gp.</td>
<td valign="top">Increased frequency of monitoring of plasma levels
of immunosuppressant drugs is recommended.</td>
</tr>
<tr>
<td stylecode="Botrule">Cyclosporine<br/>Sirolimus<br/>Tacrolimus</td>
<td stylecode="Botrule">↕ Cyclosporine <br/>↕ Sirolimus<br/>↕ Tacrolimus</td>
<td stylecode="Botrule"> </td>
</tr>
<tr>
<td stylecode="Toprule Botrule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Inhaled beta
agonist:</content>
</content>
<br/>
<br/>Salmeterol</td>
<td stylecode="Toprule Botrule" valign="top">
<br/>
<br/>↑
Salmeterol</td>
<td stylecode="Toprule Botrule">Concurrent administration of APTIVUS/ritonavir
is not recommended. The combination may result in increased risk of
cardiovascular adverse events associated with salmeterol, including
QT prolongation, palpitations, and sinus tachycardia.</td>
</tr>
<tr>
<td stylecode="Toprule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Inhaled/Nasal Steroids:</content>
</content>
<br/> </td>
<td colspan="2" stylecode="Toprule"> </td>
</tr>
<tr>
<td stylecode="Botrule" valign="top">Fluticasone</td>
<td stylecode="Botrule" valign="top">↑ Fluticasone</td>
<td stylecode="Botrule" valign="top">Concomitant use of fluticasone
propionate and APTIVUS/ritonavir may increase plasma concentrations
of fluticasone propionate, resulting in significantly reduced serum
cortisol concentrations. Co-administration of fluticasone propionate
and APTIVUS/ritonavir is not recommended unless the potential benefit
to the patient outweighs the risk of systemic corticosteroid side
effects.</td>
</tr>
<tr>
<td stylecode="Toprule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Narcotic Analgesics:</content>
</content>
<br/> </td>
<td colspan="2" stylecode="Toprule" valign="top"> </td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="top">Combinations with APTIVUS/ritonavir not studied</td>
<td rowspan="2" valign="top">Dosage increase and long-term use of
meperidine are not recommended due to increased concentrations of
the metabolite normeperidine which has both analgesic activity and
CNS stimulant activity (e.g., seizures).</td>
</tr>
<tr>
<td valign="top">Meperidine </td>
<td valign="top">↓ Meperidine, ↑ Normeperidine</td>
</tr>
<tr>
<td colspan="3"> </td>
</tr>
<tr>
<td valign="top">Methadone</td>
<td valign="top">↓ Methadone<br/>
<br/>↓ S-Methadone,
↓ R-Methadone</td>
<td valign="top">Dosage of methadone may need to be increased when
co-administered with APTIVUS and 200 mg of ritonavir.</td>
</tr>
<tr>
<td stylecode="Toprule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Oral Contraceptives/Estrogens:</content>
</content>
<br/> </td>
<td colspan="2" stylecode="Toprule"> </td>
</tr>
<tr>
<td valign="top">Ethinyl estradiol</td>
<td valign="top">↓ Ethinyl estradiol concentrations by 50%</td>
<td valign="top">Alternative methods of nonhormonal contraception
should be used when estrogen based oral contraceptives are co-administered
with APTIVUS and 200 mg of ritonavir. Patients using estrogens as
hormone replacement therapy should be clinically monitored for signs
of estrogen deficiency. Women using estrogens may have an increased
risk of non-serious rash. </td>
</tr>
<tr>
<td stylecode="Toprule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Proton Pump Inhibitors:</content>
</content> </td>
<td colspan="2" stylecode="Toprule" valign="top"> </td>
</tr>
<tr>
<td valign="top">
<br/>Omeprazole</td>
<td valign="top">
<br/>↓ Omeprazole, ↔ Tipranavir</td>
<td valign="top">Dosage of omeprazole may need to be increased when
co-administered with APTIVUS and ritonavir.</td>
</tr>
<tr>
<td colspan="3" valign="top"> </td>
</tr>
<tr>
<td stylecode="Toprule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">PDE-5 Inhibitors:</content>
</content>
</td>
<td colspan="2" stylecode="Toprule"> </td>
</tr>
<tr>
<td rowspan="3" valign="top">
<br/>
<br/>
<br/>Sildenafil<br/>Tadalafil<br/>Vardenafil</td>
<td valign="top">Only the combination of tadalafil with APTIVUS/ritonavir
has been studied (at doses used for treatment of erectile dysfunction). </td>
<td valign="top">Co-administration with APTIVUS/ritonavir may result
in an increase in PDE-5 inhibitor-associated adverse events, including
hypotension, syncope, visual disturbances, and priapism.</td>
</tr>
<tr valign="top">
<td valign="top">
<br/>↑ Sildenafil (not studied)<br/>↑ Tadalafil with first dose APTIVUS/ritonavir<br/>↔ Tadalafil
at APTIVUS/ritonavir steady-state<br/>↑ Vardenafil (not studied)</td>
<td>
<content stylecode="underline">
<content stylecode="emphasis">Use of PDE-5 inhibitors for pulmonary arterial
hypertension (PAH):</content>
</content>
<list id="l566181281398090117" listtype="unordered" stylecode="None">
<item>
<caption> </caption>
<list id="l15623122" listtype="unordered" stylecode="Disc">
<item>Use of sildenafil (Revatio) is contraindicated when used
for the treatment of pulmonary arterial hypertension (PAH) [<content stylecode="italics">see Contraindications (<linkhtml href="#Section_4.2">4.2</linkhtml>)</content>].<br/>
<br/>
</item>
<item>The following dose adjustments are recommended for use of
tadalafil (Adcirca) with APTIVUS/ritonavir:</item>
</list>
<content stylecode="underline">
<content stylecode="emphasis">Co-administration of tadalafil (Adcirca)
in patients on APTIVUS/ritonavir:</content>
</content>
<br/>
<br/>In patients receiving APTIVUS/ritonavir for at least
one week, start Adcirca at 20 mg once daily. Increase to 40 mg once
daily based upon individual tolerability.<br/>
<br/>
<content stylecode="underline">
<content stylecode="emphasis">Co-administration of APTIVUS/ritonavir in patients on tadalafil
(Adcirca):</content>
</content>
<br/>
<br/> Avoid use
of tadalafil (Adcirca) during the initiation of APTIVUS/ritonavir.
Stop Adcirca at least 24 hours prior to starting APTIVUS/ritonavir.
After at least one week following the initiation of APTIVUS/ritonavir,
resume Adcirca at 20 mg once daily. Increase to 40 mg once daily based
upon individual tolerability.</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Botrule" valign="top"> </td>
<td stylecode="Botrule" valign="top">
<content stylecode="underline">
<content stylecode="emphasis">Use of PDE-5
inhibitors for erectile dysfunction:</content>
</content>
<br/>
<br/>Concomitant use of PDE-5 inhibitors with APTIVUS/ritonavir
should be used with caution and in no case should the starting dose
of:<list id="l15895122" listtype="unordered" stylecode="Disc">
<item>sildenafil exceed 25 mg within 48 hours </item>
<item>tadalafil exceed 10 mg every 72 hours</item>
<item>vardenafil exceed 2.5 mg every 72 hours</item>
</list>Use with increased monitoring for adverse events.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule" valign="top">Warfarin</td>
<td stylecode="Toprule Botrule" valign="top">↔ S-Warfarin</td>
<td stylecode="Toprule Botrule" valign="top">Frequent INR (international
normalized ratio) monitoring upon initiation of APTIVUS/ritonavir
therapy.</td>
</tr>
</tbody>
</table>